Usefulness of Serum Pepsinogen and Gastrin as the Predictive Biomarker of Atrophic Gastritis, Intestinal Metaplasia and Gastric Cancer in Korea

Atrophic Gastritis Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02184910
• Other study ID #: 4-2013-0722
• Status: Recruiting
• Start date: December 2013
• Est. completion date: December 2023

Study information

• Verified date: March 2019
• Source: Yonsei University
• Contact: Yong Chan Lee, MD, PhD
• Phone: 82-2-2228-1960
• Email: leeyc[@]yuhs.ac
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

It is well-known that atrophic gastritis is a major risk factor for gastric cancer, which leads to variations in the serum levels of gastrin, pepsinogen (PG) I, and PGII. We want to assess the effects of age, sex, and Helicobacter pylori status on pepsinogen (PG) level for atrophic gastritis and whether gastric atrophy based on the PG test would be improved after H. pylori eradication.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 108
• Est. completion date: December 2023
• Est. primary completion date: December 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

1. over 19 years

2. the patients who have gastrointestinal discomfort or get esophagogastroduodenoscopy (EGD) for health check up

3. the patients who got the procedure, endoscopic submucosal resection (ESD) for early gastric cancer

Exclusion Criteria:

1. gastrectomy history

2. advanced gastric cancer (impossible to get the gastrectomy)

3. Helicobacter eradication history

4. the patients who have chronic disease

5. cancer patients except gastric cancer within 6 months

6. who cannot perform this study according to research's decision

7. who have bleeding tendency (ex. taking antiplatelet agent, low platelet count or abnormal coagulation time)

Related Conditions & MeSH terms

• Atrophic Gastritis
• Atrophy
• Gastritis
• Gastritis, Atrophic

Intervention

Drug:
• pepsinogen and gastrin

Locations

Country	Name	City	State
Korea, Republic of	Severance hospital	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Yonsei University

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the change of pepsinogen level before and after H. pylori eradication	to compare the change of the pepsinogen level before and after H. pylori eradication and evaluate the correlation between the pepsinogen level and the atrophic gastritis	baseline and 6 months